Liposomal Bupivacaine in Total Knee Arthroplasty

• Status: Completed
• Trial end date: 2018-03-01
• Target enrollment: 0
• Participant gender: All

Summary

Pain management after total knee arthroplasty is essential for optimized clinical outcomes and higher satisfaction. Exparel (Pacira Pharmaceuticals, Parsippany, New Jersey, USA) is a long-acting Bupivacaine extended release liposome compound that is injected peri-articularly or as regional block. The purpose of this study was to compare the analgesic efficacy of single administration of Exparel for local peri-articular infiltration versus adductor canal regional block.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bronx-Lebanon Hospital Center Health Care System
• Treatments: Bupivacaine

Criteria

Inclusion Criteria:

• primary knee osteoarthritis undergoing unilateral knee replacement

Exclusion Criteria:

• hypersensitivity and/or allergies to local anesthetics or previous knee surgery